Flagship, Pfizer team up in deal worth up to $7 billion
The new Pfizer partnership with Flagship will fund the development of up to 10 drug candidates.
Related Articles
STAT readers respond to First Opinion essays on site-neutral payments, free medical school tuition, and more
It takes great minds with a lot of heart to find a cure for diseases like Duchenne muscular dystrophy.
Massive amounts of H5N1 vaccine would be needed if there’s a bird flu pandemic. Can we make enough?
The first signs that H5N1 avian flu was starting to spread from person to person would trigger a race to produce massive amounts of vaccine.
Anticompetitive hospital mergers skate by due to FTC’s shallow resources
The agency simply doesn’t have enough resources to challenge but 1% of hospital mergers, so they continue to result in less competition and higher prices.
Novo Nordisk’s move to discontinue an insulin leaves patients to ‘pick up the pieces’
Novo Nordisk’s move to discontinue its Levemir insulin has left patients to “pick up the pieces.”
FTC’s noncompete ban would force sweeping changes in health care, if it survives legal battle
The FTC’s noncompete ban could force sweeping changes in the health care industry, but implementation of the rule will almost certainly be held up by…
NIH postdocs will get a raise next year — but not as much as they hoped
The NIH will raise the minimum salary for postdocs to $61,008, responding to calls from young life scientists to provide a living wage.
Health care lobbying giants spent big as little got done in Congress
Congress did nothing this spring to rein in how pharmacy benefit managers operate, and the PBM industry spent big to get that result, new disclosures…
Day One drug for common childhood brain tumor approved by FDA
Researchers hope the pill, which will be marketed as Ojemda, may allow more patients to reach adulthood without highly toxic treatments such as radiation.
Telehealth startups see an opportunity in long-ignored, complex chronic diseases
Easily a decade can pass before someone with a complex chronic condition gets a proper diagnosis. New telehealth companies aim to shorten that time and…
Trump surrogates hint at how he could reshape U.S. health care policy
Donald Trump’s health care priorities remain fuzzy. But one thing is certain: A second Trump administration would put its own stamp on a host of…